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Triple-negative breast cancer (TNBC), a subtype distinguished by negative immunohistochemical assays for expression of the
estrogen and progesterone receptors (ER/PR) and human epidermal growth factor receptor-2(HER2) represents 15% of all breast
cancers. Patients with TNBC generally experience a more aggressive clinical course with increased risk of disease progression and
poorer overall survival. Furthermore, this subtype accounts for a disproportionate number of disease-related mortality in part
due to its aggressive natural history and our lack of eﬀective targeted agents beyond conventional cytotoxic chemotherapy. In this
paper, we will review the epidemiology, risk factors, prognosis, and the molecular and clinicopathologic features that distinguish
TNBC from other subtypes of breast cancer. In addition, we will examine the available data for the use of cytotoxic chemotherapy
in the treatment of TNBC in both the neoadjuvant and adjuvant setting and explore the ongoing development of newer targeted
agents.
1.Triple-NegativeBreast Cancer:Adjuvant
TherapeuticOptions
Each year more than 1.3 million new cases of breast cancer
are diagnosed worldwide. In spite of numerous advances
in prevention, surgical resection, and adjuvant radiother-
apy and chemotherapy, it is estimated that approximately
450,000 women will die of this disease globally each year
[1]. Triple-negative breast cancer (TNBC), a subtype distin-
guished by negative immunohistochemical assays for expres-
sion of the estrogen and progesterone receptors (ER/PR)
and human epidermal growth factor receptor-2 (HER2),
represents approximately 15% of all breast cancers. Patients
diagnosedwithTNBCgenerallyexperienceamoreaggressive
clinical course exacerbated by the lack of eﬀective targeted
therapies. Moreover, despite best available therapy, TNBC
accounts for a disproportionate number of breast cancer-
related deaths, further highlighting the need for novel
therapeutic approaches for the management of this high-
risk subset of patients [2–4]. In this paper, we will review
the epidemiology, risk factors, prognosis, and the molecular
and clinicopathologic features that distinguish TNBC from
other subtypes of breast cancer. In addition, we will examine
the available data for the use of cytotoxic chemotherapy
in the treatment of TNBC in both the neoadjuvant and
adjuvant setting and explore the ongoing development of
newer targeted agents.
2.Clinicopathologicand Molecular
Features of TNBC
Human breast cancers represent a heterogenous disease
group characterized by varied clinical presentations and
responses to therapy. In the past decade, the use of
complementary DNA (cDNA) microarrays has furthered
our understanding of the underlying biologic diversity of
these tumors well beyond the identiﬁcation of hormone
receptorandHER2status,toincludedistinctgeneexpression
proﬁles which correlate with disease progression and clinical
outcomes.
Perou, Sørlie, and colleagues have identiﬁed 5 molec-
ularly distinct gene expression proﬁles that may one day
allow for clinically relevant classiﬁcation of breast cancer
[5–7]. This diversity is apparent within the triple-negative
subgroup as well, evidenced by the identiﬁcation of multiple2 Chemotherapy Research and Practice
molecular proﬁles which demonstrate low expression of ER,
PR, and HER2 including the basal-like, claudin-low, and
molecular apocrine/ER(−) class A subtypes [8–10]. One
such group, the basal-like breast cancers (BLBC), expresses
minimal levels of ER/PR/HER2 and high levels of CK 5/6,
CK 14, CK 17, p-cadherin, caveolin-1, carbonic anhydrase
IX gene (CA IX), p63 (a member of the p53 family of
transcriptionfactors andamyoepithelialstemcellregulator),
and epidermal growth factor receptor (EGFR or HER1)
similar to their cell of origin in normal breast tissue [11].
Although not completely identical, basal-like and triple-
negative breast cancers share numerous molecular features
with up to 70% concordance between the two subgroups
[12–15]. Interestingly, tumors associated with germline
mutations in BRCA-1 demonstrate a signiﬁcant overlap in
their clinical and molecular presentation with basal-like
tumors [16, 17]. BRCA-1-associated tumors are generally
triple-negative [18, 19] and cluster alongside the basal-like
tumors on microarray [7] with a signiﬁcant proportion
expressing CK 5/6, 14, 17, p-cadherin, and EGFR [17, 19–
22]. Studies that have reviewed the histological presentation
of TNBC and BLBC demonstrate that >90% of these tumors
arise from the breast ducts and are often associated with
higher nuclear and histologic grade, high mitotic index, and
more aggressive phenotypic features [2, 13, 19, 23–25].
3.Epidemiology
Epidemiologic studies demonstrate that women diagnosed
with TNBC manifest a signiﬁcantly diﬀerent set of clini-
copathologic features and risk factors when compared to
women with other subtypes of breast cancer. TNBC com-
prises approximately 15% of all breast cancers diagnosed;
however, in certain select populations, the prevalencemay be
higher, for example, among premenopausal African Ameri-
can and Hispanic patients [4, 23, 25–29]. Based on multiple
population-based studies, women with TNBC on average
are younger at diagnosis and have disease associated with
both modiﬁable and nonmodiﬁable risk factors including
earlier age at menarche and at ﬁrst pregnancy, increased
parity, decreased breastfeeding, higher BMI, and lower
socioeconomic status [2, 25, 26, 28, 30–36].
4.PatternsofRecurrenceand Prognosis
Population-based studies have conﬁrmed the increased rate
of breast cancer-related deaths among patients with TNBC
and have identiﬁed distinct patterns of recurrence for this
subgroup [2, 23]. Patients diagnosed with TNBC have a
higher likelihood of recurrence within the ﬁrst three years of
diagnosis anddeathfrom diseasewithin theﬁrst ﬁveyears [2,
37].Additionally,oncemetastaticdisease hasbeenidentiﬁed,
patients with TNBC and BLBC experience shorter survival
times in comparison to patients with other tumor subtypes
[2, 24, 27]. Among TNBC patients, recurrences beyond 5
years are less common and at 10 years, overall survival rates
among the varying subgroups are roughly equivalent [38].
Women with TNBC more often develop visceral ver-
sus osseous metastases when compared to their hormone
receptor-positive counterparts [4, 39]. In a large multicenter
study which included >2000 patients with TNBC, Lin and
colleagues demonstrated that women with TNBC were
more likely to develop lung (Odds Ratio (OR) 2.27, 95%
conﬁdence interval (CI) 1.50, 3.43; P = .0001) or brain
metastases (OR 5.32, 95% CI 2.85, 9.91; P<. 0001) as
their ﬁrst site of recurrence. In comparison, these women
demonstrated a much lower risk of bone recurrence (OR
0.23, 95% CI 0.16, 0.33; P<. 0001) [25]. Numerous studies
have demonstrated an increased rate of CNS metastases in
women with TNBC [40–42]. In a large single-institution
retrospective analysis, 1,138 women with stage I-III TNBC
were identiﬁed, of which 29% had developed recurrence
at median ﬁve-year followup. Of those with documented
recurrence, 21% had developed brain metastases. Median
survival for those with brain metastases was 25 weeks with
survival rates at 6 months and 12 months of 48% and
25%, respectively [43]. Similar results were seen in other
studies and when compared to patients with phenotypically
diﬀerent breast cancers, women with TNBC experienced
shorter median survival after diagnosis of CNS involvement
[41, 44].
5.TherapeuticOptions
5.1. Chemotherapy. To date, many studies have examined
the utility of traditional chemotherapy for the treatment
of patients with TNBC and have conﬁrmed the beneﬁts
of these agents in both the adjuvant and neoadjuvant
settings. A meta-analysis from the Early Breast Cancer
Trialists’ Collaborative Group (EBCTCG)was one of the ﬁrst
reviews to determine the eﬃcacy ofpolychemotherapy inthe
treatment of ER-poor individuals. Over 6000 women with
ER-poor breast cancer, treated in 46 separate randomized
trials of adjuvant polychemotherapy (CMF X6 45%; FAC
or FEC X6 31%, other 24%) in the prepaclitaxel era were
examined. At ten-years followup, the women treated with
polychemotherapy demonstrated a signiﬁcantly reduced risk
of recurrence (age <50 hazard ratio (HR) 0.73, age 50–
69 HR 0.82) as well as both breast cancer-related (age <
50 HR 0.73, age 50–69 HR 0.86) and all-cause mortality
(age < 50 HR 0.75, age 50–69 HR 0.87) [45]. As many of
these trials were initiated prior to uniform HER2 testing,
information regarding the true proportion of TNBC in the
trial population remains unknown. Nevertheless, the results
of this large meta-analysis strengthened the hypothesis
that improved outcomes could be achieved in this high-
risk population with the use of multiple chemotherapeutic
agents.
Similarly, Berry and colleagues completed a retrospective
analysis regarding the eﬃcacy of adjuvant chemotherapy
in relation to ER status among women enrolled in three
adjuvant chemotherapy trials coordinated by the Cancer
A n dL e u k e m i aG r o u pB( C A L G B )a n dt h eU SB r e a s tI n t e r -
group (CALGB 8541, 9344/INT 1048, 9741/INT C9741).
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women with ER-negative tumors treated with regimens
which included higher doses, taxanes, and dose-dense (dd)
scheduling fared better in terms of risk of recurrence
and overall survival. When examined in total, ER-negative
women who received dd doxorubicin, cyclophosphamide
followed by paclitaxel (AC→T) compared to low-dose
cyclophosphamide, doxorubicin, and 5-ﬂuorouracil (CAF)
experienced a 55% (Conﬁdence Interval (CI) 37–68%)
relative risk reduction in recurrence. In comparison, women
with ER-positive disease experienced a 26% risk reduction,
(CI −4–48%). Furthermore, the absolute improvement in
disease-free survival (DFS) (22.8% versus 7% P<. 001) and
overall survival (16.7% versus 4.0% P<. 001) incurred by
the ER-negative subgroup further underscored the beneﬁts
of multidrug chemotherapy regimens in this subgroup
[46].
When analyzed individually, CALGB 9344 and 9741 not
only highlighted the therapeutic beneﬁt of taxanes in the
adjuvant setting but also contributed to the observation
that ER-negative individuals speciﬁcally may experience
preferentially improved outcomes from use of taxane-
inclusive regimens. Unplanned subset analyses in both of
the aforementioned studies demonstrated a trend towards
improved risk reduction in terms of recurrence for women
with ER-negative disease (9344: 28% versus 9%; 9741: 32%
versus 19%) [47, 48]. Further examination of the HER2(−)
subgroup, demonstrated that women who were both ER and
HER2 negative realized a statistically signiﬁcant improve-
ment in DFS with the addition of paclitaxel therapy (P =
.002) whereas ER+ HER2(−) individuals did not experience
a similar beneﬁt (P = .71), thereby supporting the inclusion
of taxanes in adjuvant therapy for the treatment of patients
with TNBC [48]. Interestingly, women with HER2+ breast
cancer, regardless of hormone receptor status, experienced a
statisticallysigniﬁcantimprovementintermsofDFSwiththe
addition of paclitaxel chemotherapy. However, comparisons
between women with ER/PR(−)H E R 2 ( −)d i s e a s ea n d
those with ER/PR(−) HER2(+) disease remain complicated,
because of the retrospective nature of the analyses and the
increasing use of anti-HER2 therapy.
Several studies have substantiated the positive impact
of chemotherapy in the treatment of patients with TNBC
in the neoadjuvant setting as well. Among 1,118 patients
treated with neoadjuvant chemotherapy, (>80% treated with
anthracycline-basedregimen;53%treatedwithanadditional
taxane), patients with TNBC had a signiﬁcantly higher rate
of pathologic complete response (pCR) in comparison to
patients with non-TNBC (22% versus 11%; P = .034).
And despite an overall worse progression-free survival (PFS)
and overall survival (OS) among patients with TNBC, those
individuals who achieved a pCR had similar overall survival
r a t e sa sn o n - T N B Cp a t i e n t sw i t hp C R[ 4]. A retrospective
analysisofpatientstreatedpredominantlywithanthracycline
and anthracycline/taxane containing preoperative regimens
(91% and 58%, resp.), which included 317 patients with
TNBC, demonstrated a similar rate of pCR among this
subgroup, 22.4%. Comparatively patients with hormone
receptor-negative disease attained signiﬁcantly higher rates
of pCR (24% versus 8% P>. 001) than the hormone
receptor-positive group. Similar to that shown in the Liedtke
trial [4], patients who achieved a pCR also experienced
improved PFS and OS [49]. When objective response to
neoadjuvant chemotherapy (weekly T × 12 followed by
ﬂuorouracil, doxorubicin, cyclophosphamide (FAC) × 4)
was examined in relation to the established molecular
subtypes ofbreast cancer, Rouzieret al. identiﬁed the highest
rates of pCR among the BLBC (45%; CI 24–68%) and
erbB2+ (45% CI 23–68%) subgroups. In comparison, of
the 30 luminal breast cancers only 2 achieved a pCR (7%
CI 1–22%) [50]. Carey et al. demonstrated similar results
when patients were treated with 4 cycles of neoadjuvant
AC. Furthermore, patients who achieved a complete pCR,
regardless of molecular subtype, experienced better out-
comes in terms of distant disease-free survival [51]. Despite
the varied neoadjuvant regimens studied in these trials and
many others, the consistently higher rates of pCR among
the TNBC/BLBC subgroup in response to chemotherapy
reaﬃrms the utility of this therapeutic strategy in the
treatment of this subgroup.
Many trials support the use of cytotoxic agents for the
treatment of patients with TNBC; however, the superiority
ofone regimen overanother has not been clearly established.
For example, a retrospective review of the MA5 trial,
(adjuvant cyclophosphamide/epirubicin/ ﬂuorouracil (CEF)
versusCMF),delineatedoverallsurvivalinrelationtomolec-
ular phenotype. Patients with BLBC who received CMF were
shown to have a superior 5-year overall survival rate in
comparison to those who received the anthracycline-based
regimen (71% versus 51%) [52]. In another retrospective
review,Colleonietal.demonstratedthatpatientswith TNBC
treated with CMF (either 3 or 6 cycles) experienced the
greatest beneﬁt from chemotherapy in terms of relative risk
reduction(HR0.46,CI0.29–0.73,P = .009)when compared
toindividualswithhormonereceptor-and/orHER2-positive
disease [53]. Furthermore, review of the literature fails to
explain whether response rates to chemotherapy among this
subgroup are a result of the eﬃcacy of speciﬁc regimens or
the increased chemosensitivity of individuals with TNBC.
More recently, a number of preclinical studies examining
the activity of platinum agents in the treatment of TN
and BRCA1-associated breast cancers have demonstrated
increased sensitivity to these agents. BRCA1-associated
tumors are deﬁcient in the genes that encode for proteins
critical in DNA integrity, genomic stability, and DNA repair.
In preclinical models of BRCA1-deﬁcient breast cancers,
there is an increased susceptibility to DNA-damaging agents,
particularly those able to induce double-strand breaks such
as cisplatin or carboplatin [54–57]. Byrski et al. treated 10
womenwith BRCA1-associatedbreast cancer,(9with known
TNBC) with preoperative single-agent cisplatin (75mg/m2
every 3 weeks × 4). All but one patient on the trial achieved
a pCR, and she was noted not to have completed all 4
cycles of chemotherapy [58]. Given the small numbers of
patient in this trial and the limited followup, it is diﬃcult to
draw conclusions regarding reduction in risk of recurrence
and survival. However, these data do suggest the activity of
platinum agents in this subgroup and warrant further study
in prospective trials as detailed below.4 Chemotherapy Research and Practice
TNBC share numerous clinical, molecular, and patho-
logic features with BRCA mutation-related breast cancers
including altered BRCA function and a high degree of
genomic instability as well as impaired DNA damage repair.
Consequently, many studies have been initiated to study
the eﬃcacy of platinum salts in this subgroup. Silver and
colleagues tested the eﬃcacy of neoadjuvant cisplatin in a
TNBCpopulationnot enriched for BRCA-mutationcarriers.
Eighteen of the 28 patients experienced a clinical response to
therapy demonstrating either a partial or complete response
with6achieving completepathologicremission. Two ofthe6
patients who attained pCR were germline BRCA1-mutation
carriers. As a correlate, levels of BRCA1 mRNA expression
andBRCA1promotermethylationweremeasured inrelation
to response to therapy. Both lower levels of BRCA expression
as well as BRCA promoter methylation, which is inversely
proportional to BRCA expression, were correlated with
response to cisplatin therapy suggesting that a subgroup of
TNBC patients may demonstrate a “BRCA-like” phenotype
which predisposes them to cisplatin-sensitivity [59].
Most recently, the BALI-1 trial randomized 173 patients
with metastatic TNBC to receive either cisplatin alone versus
cisplatin in combination with cetuximab. Final analysis of
the trial demonstrated a modest yet statistically signiﬁcant
improvement in PFS among patients who received combi-
nation therapy, 1.5 versus 3.7 months (HR 0.675 CI 0.470–
0.969, P = .032). Notwithstanding the doubling of the
overall response rate in the combination arm (10.3% versus
20%), the study failed to meet its primary endpoint of
greater than a 20% response among patients who received
both cisplatin and cetuximab [60]. This highlights the need
for further studies to examine the eﬃcacy of single-agent
platinum therapy to treat TNBC as well as the use of targeted
therapies, like cetuximab, in an unselected population.
Numerous trials are currently underway in the adjuvant
and neoadjuvant setting to prospectively study the eﬃcacy
of polychemotherapy, including combinations with newer
chemotherapeutic agents and novel targeted therapies.
(i) CALGB 40603 is a randomized Phase II trial where
patients are enrolled in 1 of 4 arms which include:
Arm 1: weekly paclitaxel x12 followed by dd AC x4,
Arm 2: Arm 1 + bevacizumab every 2 weeks, Arm 3:
Arm 1 + carboplatin, and Arm 4: Arm I + bevaci-
zumab as in arm II + carboplatin as in arm III
(NCT00861705).
(ii) A Phase III trial enrolling patients into either do-
cetaxel/anthracycline (epirubicin versus doxorubi-
cin)/cyclophosphamide versus docetaxel and cyclo-
phosphamide is set to assess the added beneﬁt of
anthracycline-containing preoperative regimens in
TNBC (NCT00912444).
(iii) A randomized Phase III study of standard adjuvant
chemotherapy alone or followed by 1 year of metro-
nomic capecitabine (650mg/m2 BID) is underway
with the primary endpoint of DFS. (NCT01112826)
Thus far, capecitabine has not been studied specif-
ically in the triple-negative population. Addition-
ally, the data which currently exist are based on
retrospective subgroup analyses which demonstrated
that treatment with capecitabine resulted in limited
activity in comparison to standard chemotherapy
in the adjuvant setting as well as poorer survival
outcomes in comparison to non-TNBC patients in
the metastatic setting [61–63].
(iv) A Phase II study of ixabepilone in the neoadjuvant
setting demonstrated promising results; in subgroup
analysis, patients with TNBC demonstrated a pCR
rateof19%(CI9–34%)[64].However,amore recent
neoadjuvant Phase II trial randomizing patients to
AC followed by ixabepilone versus AC followed by
paclitaxel did not demonstrate a signiﬁcant diﬀer-
ence in pCR rates between the two regimens, 34%
versus 41% [65]. In light of this, the two adjuvant
Phase III trials (PACS08 (NCT00630032)and TITAN
(NCT00789581)) initiated to compare ixabepilone
directlywith morecommonlyusedtaxaneshavebeen
terminated by Bristol-Myers Squibb.
6.Targeted Therapies
6.1. Antiangiogenic Agents. Agents that target angiogenesis
are appealing for the treatment of TNBC because higher
levels of vascular endothelial growth factor (VEGF) and
VEGF-2 have been shown in women with TNBC suggesting
its potential as a prognostic tool as well as a putative
target for therapeutic intervention [66, 67]. Bevacizumab,
a humanized monoclonal antibody to VEGF, is approved
by the FDA for the treatment of several solid tumors and
was granted accelerated approval for the treatment of ﬁrst-
line MBC in combination with paclitaxel [68]. At this time,
the approval of bevacizumab and paclitaxel for this ﬁrst-line
indication is under review.
Bevacizumab has been studied in three randomized
Phase III trials in combination with chemotherapy for
the ﬁrst-line treatment of metastatic breast cancer. E2100
randomized >700 women to receive weekly paclitaxel with
or without bevacizumab. Women who received bevacizumab
experienced a signiﬁcantly higher objective response rate
(36.9% versus 21.2%, P ≤ .001) and improvement in PFS
(11.8 versus 5.9 months, P ≤ .001). Subset analysis of
the women with ER/PR(−) disease, the majority of whom
were negative for HER2 (>90%), demonstrated a robust
prolongationofPFSincomparisontothehormonereceptor-
positive patients [69].
The beneﬁt of bevacizumab for patients with triple-
negative MBC was replicated in AVADO, a placebo-con-
trolled study evaluating the addition of bevacizumab (at 2
doses: 7.5mg/kg or 15mg/kg) to docetaxel. PFS was signiﬁ-
cantly improved for those patients who received docetaxel in
combination with bevacizumab when compared to women
who received docetaxel monotherapy. Median PFS for doc-
etaxel monotherapy in comparison to the bevacizumab7.5
and bevacizumab15 groups was 8.0 versus 8.7 (HR 0.79
P = .03) and 8.8 (HR 0.72 P = .001) months, respectively.
Unplanned subgroup analysis of the ER/PR/HER2(−)s ubs et
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a whole (bevacizumab7.5: HR 0.83; bevacizumab15: HR 0.68)
[70].
The third Phase III trial of bevacizumab in the ﬁrst-
line setting randomized patients to receive bevacizumab or
placebo in combination with several diﬀerent chemotherapy
options (anthracyclines, taxanes, and capecitabine). Based
on investigator assessment, the addition of bevacizumab
to capecitabine or an anthracycline/taxane resulted in sta-
tistically signiﬁcant prolongation in PFS as compared to
placebo (8.6 versus 5.7 months HR 0.69 P = .0002 and
9.2 versus 8.0 months HR 0.65 P = .0001, resp.) [71].
Further analysis of the ER/PR/HER2-negative subgroup
demonstrated a nonsigniﬁcant improvement in the median
PFSinboththecapecitabine(4.2versus6.1months,HR0.72,
CI 0.49–1.06) and anthracycline/taxane cohorts (8.2 versus
14.5 months, HR 0.78, CI 0.53–1.15) [72].
Although all three trials failed to demonstrate an OS
beneﬁt with the addition of bevacizumab in the metastatic
setting, improvements in response rate and PFS were
achieved across all subtypes suggesting activity in breast can-
cer. Furthermore, despite the inherent limitations associated
with unplanned retrospective subgroup analyses all three
trials demonstrated at least a trend towards improved RR
and PFS with the addition of bevacizumab in patients with
TNBC.
Currently, there are multiple Phase II/III trials designed
to test the eﬃcacy of bevacizumab in the neoadjuvant/adju-
vant setting. Three Phase II studies are currently accruing
patients to assess the beneﬁts of including bevacizumab in
conjunction with platinum agents in the neoadjuvant setting
for patients with TNBC. As previously discussed, CALGB
40603is a multiarmtrial comparing weekly T followed by dd
AC with the addition of either bevacizumab or carboplatin
alone or in combination. (NCT00861705) The NEAT trial
is a single-arm, open-label study of docetaxel/carboplatin
in combination with bevacizumab given every 3 weeks
for 6 cycles preoperatively. (NCT01208480) In a similar
study based at the University of Tennessee Cancer Insti-
tute, patients will receive neoadjuvant nanoparticle albumin
bound (nab-) paclitaxel (day 1, 8, 15), carboplatin (day
1), and bevacizumab (day 1, 15) over the course of a 28-
day cycle × 4 cycles followed by ddAC × 4 in addition to
bevacizumab for the ﬁrst two cycles. In this trial to assess the
utilityof maintenance bevacizumab, postoperativelypatients
will receive 8 cyclesof bevacizumab givenevery 2 weeks for a
total of 16 doses (NCT00777673).
In the adjuvant setting, the BEATRICE study randomizes
patients with TNBC to either standard adjuvant chemother-
apy (anthracycline ± taxane or taxane only) or adjuvant
chemotherapy in combination with bevacizumab x1 year
to assess the primary endpoint of disease-free survival
(NCT00528567).
Additionally multitargeted small molecule tyrosine
kinase inhibitors (TKIs), such as sunitinib and sorafenib,
which inhibit numerous targets in the antiangiogenesis
pathway, have been evaluated for the treatment of MBC.
Unfortunately, these agents have thus far demonstrated
modest single-agent activity [73–75]a n dh a v ef a i l e dt o
improve PFS in two large Phase III trials in combination
with chemotherapy, (SUN1064:sunitinib plus docetaxel ver-
sus docetaxel; SUN1099: sunitinib plus capecitabine versus
capecitabine) [76, 77]. There are currently two Phase I/II
studies underway in the neoadjuvant setting which were
developed to assess the beneﬁt of platinum/taxane-based
chemotherapy in combination with these antiangiogenic
TKIs (NCT00887575; NCT01194869).
6.2. Poly(ADP-ribose) Polymerase (PARP) Inhibitors. PARP
is an essential nuclear enzyme that is involved in the
recognition of DNA damage and facilitation of single-
strand DNA repair through the base excision repair (BER)
pathway.FollowingdetectionofaDNAstrand break,PARP1,
the predominant cellular PARP catalyzes the synthesis and
transfer of ADP-ribose polymers to target proteins using
NAD+ as substrate. As a result, PARP recruits other repair
e n z y m e sa n df a c i l i t a t e sD N Ar e p a i ra n dc e l ls u r v i v a l .B R C A 1
and BRCA2 genes encode for proteins critical for DNA
integrity and genomic stability. BRCA1 and BRCA2 proteins
are essential for cell division, DNA error control, DNA
repair, and apoptosis. In patients with BRCA loss (hereditary
mutation), inhibition of PARP induces synthetic lethality
which means that DNA damage is irreparable and leads to
cell death in homozygote tumor cells, but not in normal
tissue heterozygote cells which have one functional BRCA
allele [78–84].
In 2005, Farmer and colleagues showed that BRCAd-
eﬁcient breast cell lines were extremely sensitive to PARP
inhibition[81].Single-agentPARPinhibitorsledtoimpaired
single-strand break (SSB) repair causing double-strand
breaks (DSBs) to occur in replicating cells. In BRCA wild-
type cells, DSBsare repaired via homologousrecombination,
but in BRCA mutant cells, this compensatory repair pathway
isimpaired leading tocomplexrearrangements, loss ofrepair
mechanisms, and cell death.
As discussed previously, preclinical tumor models
of BRCA-associated breast cancers have demonstrated
increased sensitivity to therapies which induce DNA damage
such as alkylators and radiation (Table 1)[ 3, 54–57, 85].
Thus, numerous studies in the metastatic setting have paired
PARP inhibitors with agents such as platinums and te-
mozolomide. These clinical trials have shown encouraging
activity in severalsolid tumors with acceptablesafety proﬁles
(Table 2). Tutt et al. conducted a Phase II study of single
agent olaparib in women with BRCA-associated breast
cancer. Patients received olaparib at one of two doses. After
an interim analysis, patients in the low-dose cohort who had
not progressed were oﬀered the option of dose escalation on
study. The results of the trial indicated signiﬁcant objective
response rates of 41% (CI 25–59%) among the cohort
receiving 400mg BID and 22% (CI 11–41%) among the
cohortreceiving100mgBIDwithlimitedtoxicity.Signiﬁcant
prolongation of median PFS was also demonstrated in
both cohorts, (maximal-dose cohort 5.7 months (CI 4.6–
7.4), low-dose cohort 3.8 months (CI 4.6–7.4)) [86]. These
ﬁndings suggest that this approach can induce synthetic
lethality in homologous recombination repair-deﬁcient cells
in general and BRCA deﬁcient cells in particular.6 Chemotherapy Research and Practice
Table 1: ClinicopathologicalFeatures of TNBC versus BLBC versus BRCA-associated Breast Cancer.
Characteristics Triple-negative breast cancer Basal-like breast cancer BRCA-associated breast cancer
Receptor status Negative Negative Often negative
HER2 Status Negative Negative Negative
Cytokeratin 5/6, 17 Often positive Positive Often positive
EGFR expression Often positive Often positive Often positive
p53 Often mutated Often mutated Often mutated
BRCA status
May be dysfunctional secondary
to diminished expression or
increased expression of negative
regulators of the BRCA pathway
May be dysfunctional secondary
to diminished expression or
increased expression of negative
regulators of the BRCA pathway
Inactivated secondary to a
hereditary mutation
Molecular gene
expression proﬁle Often basal-like Basal-like Often basal-like
Histology Ductal/poorly
diﬀerentiated/high grade
Ductal/poorly
diﬀerentiated/high grade
Ductal/poorly
diﬀerentiated/high grade
Given the clinical, histologic, and molecular overlap
between BRCA-1-associated tumors and TNBC, multiple
investigators have theorized that PARP inhibitors may prove
eﬃcacious in this subgroup as well. In a Phase II study
O’Shaughnessy and colleaguesrandomly assigned patientsto
receivecarboplatin and gemcitabinealone or in combination
with iniparib, an intravenous PARP inhibitor. The data
from this trial showed signiﬁcant improvement in clinical
beneﬁt rate (CBR = CR + partial response + stable disease
(SD) ≥6 months; 56 versus 34%, P = .01), median
PFS (5.9 versus 3.6 months HR 0.59, P = .01), and
median OS (12.3 versus 7.7 months HR = 0.57, P = .01)
among those individuals who were treated with iniparib and
chemotherapy when compared to chemotherapy alone [87].
This work launched a randomized phase III trial evaluating
iniparib in combination with carboplatin and gemcitabine
versus chemotherapy alone. A recent press release indicates
that the study did not reach signiﬁcance for its coprimary
endpoints of OS and PFS. Similar to results seen in the Phase
II trial, the combination of iniparib and chemotherapy in
the 2nd and 3rd line settings were reported to demonstrate
an increase in OS and PFS. The data from this trial have yet
to be fully presented, and, thus, the role for this agent and
other PARP inhibitors for the treatment of metastatic triple-
negative breast cancer remains unclear [88].
Trials incorporating PARP inhibitors, alone or with con-
comitant cytotoxic agents, are currently being developed in
the neoadjuvant/adjuvant BRCA-associated and TNBC pop-
ulations Two Phase II trials are currently accruing patients
in the neoadjuvant setting either in combination with
platinum agents or taxanes. (NCT00813956;NCT01204125)
An adjuvant Phase II trial is underway which random-
izes patients with residual disease after nonplatinum-based
neoadjuvant chemotherapy and deﬁnitive surgery to receive
either cisplatin alone or in combination with PF-01367338.
(NCT01074970).
6.3. EGFR Inhibitors. EGFR is expressed in approximately
60% of TNBC [89]. Preclinical work in known TNBC cell
lines demonstrated a synergistic decline in proliferation
when EGFR TKIs were combined in vitro with either
docetaxel or carboplatin. In contrast, as single agents, both
erlotinib, a TKI targeting EGFR, and cetuximab, a mon-
oclonal antibody to EGFR, demonstrated minimal single-
agent activity [90]. Clinically, EGFR inhibitors have thus
far been studied in the metastatic setting. TBCRC 001, a
randomized Phase II multicenter trial, examined sequential
cetuximab followed by carboplatin atthe time ofprogression
versus concurrent cetuximab/carboplatin in patients with
pretreated TNBC. Given the poor single agent response rate
to cetuximab in the sequential arm, this arm of the trial was
closed to accrual early. Those patients receiving cetuximab
in conjunction with carboplatin demonstrated a response
rate of 18% and a clinical beneﬁt (partial response or SD ≥
6 months) of 27%. Nevertheless, a majority of patients
progressed rapidly on both arms with a reported mean PFS
of 2.0 months in the study [91]. A second randomized Phase
II study enrolled patients in either a chemotherapy only arm
where they received irinotecan/carboplatin (Day 1, 8) versus
a combination arm of cetuximab and chemotherapy. Among
patientswithTNBC,preliminary datafromthistrial suggests
improved response rates in the combination cetuximab
and chemotherapy arm (39% versus 19%). However no
signiﬁcant improvement in PFS or OS was reported in any
of the subgroups and increased toxicity resulted in dose
reductions for both study arms [92]. The BALI-1 trial, as
reviewed earlier, failed to meet its prespeciﬁed endpoint but
did suggest the activity of cetuximab in combination with
cisplatin in patients with TNBC.
Two Phase II studies are currently open to test the
eﬃcacy of cetuximab in combination with preoperative
chemotherapy, ixabepilone (NCT01097642) and docetaxel
(NCT00600249). A neoadjuvant study is accruing patientsChemotherapy Research and Practice 7
Table 2: Neoadjuvant/Adjuvant clinical trials for patients with triple-negative breast cancer∗.
NCI ID Status Primary location Study type Setting
adjuvant Stage Regimen
Chemotherapy
NCT00861705 Recruiting Miriam Hospital
(Providence, RI) Phase II Neoadjuvant II-III
Arm A: Paclitaxel D1 weekly × 12
weekly → ddAC D1 × 4c y c l e s
Arm B: Arm A + Bevacizumab
q2wks (weeks 1, 3, 5, 7, 9, 10, 11, 13,
15, 17)
Arm C: Arm A + Carboplatin
q 3 w k s( w k s1 ,4 ,7 ,1 0
Arm D: Arm A + Bevacizumab as in
Arm B + Carboplatin as in Arm C.
NCT00912444 Recruiting
ShanghaiJiao Tong
University School of
Medicine (Shanghai,
China)
Phase III Neoadjuvant
T2N1 OR
T3-4/N0-3 OR
T0-4/N2-3
Arm A: Docetaxel 75mg/m2 &
Doxorubicin 50mg/m2 OR
Epirubicin 60mg/m2 &
Cyclophosphamide 500mg/m2
D1 × 6 cycles (cycle = 21 days)
Arm B: Docetaxel 75mg/m2 &
Cyclophosphamide 500mg/m2
D1 × 6 cycles (cycle = 21 days)
NCT01112826 Recruiting
Sun Yat-sen University
Cancer Center
(Guangzhou, China)
Phase III Adjuvant T1c-T3, pN0-2
Arm A: Standard adjuvant
chemotherapy followed by
capecitabine 650mg/m2 BID × 1y r
Arm B: standard adjuvant
chemotherapy
NCT00789581 Active/Not
recruiting
Sarah Cannon
Research Institute
(Nashville, TN)
Phase III Adjuvant
Node negative
T1c-T3 OR
Node positive
pN1mi -N2b)
Arm A: Doxorubicin 60mg/m2 &
Cyclophosphamide 600mg/m2
D1 × 4 cycles (cycle = 21 days) →
Ixabepilone at 40mg/m2 D1 × 4
cycles (cycle = 21 days)
Arm B: Doxorubicin 60mg/m2 &
Cyclophosphamide 600mg/m2
D1 × 4 cycles (cycle = 21 days) →
Paclitaxel at 80mg/m2 D1 weekly ×
12 weeks
NCT00630032 Active/Not
recruiting
Centre Regional Rene
Gauducheau
(Nantes-Saint
Herblain, France)
Phase III Adjuvant
Node-positive
disease OR
node-negative
disease: II-III
OR pT1-4
Arm A: Epirubicin & 5-Fluorouracil
& Cyclophosphamide D1 × 3c y c l e s
(cycle = 21 days) → Docetaxel
D1 × 3 cycles (cycles = 21 days)
Arm B: Epirubicin & 5-Fluorouracil
& Cyclophosphamide D1 × 3c y c l e s
(cycle = 21 days) → Ixabepilone
D1 × 3 cycles (cycles = 21 days)
NCT01216111 Available Fudan University
(Shanghai,China)
Expanded
Access Adjuvant I-IIIA
Paclitaxel 100mg/m2 & Cisplatin
AUC = 2 D1, 8, 15 × 6c y c l e s
(cycle = 28 days)
NCT01276769 Recruiting
Cancer Institute
Hospital/Chinese
Academy of Medical
Sciences (Beijing,
China)
Phase II Neoadjuvant IIa-IIIc (no T4
disease)
Arm A: Paclitaxel 175mg/m2 D3 &
Epirubicin 75mg/m2 D1 ,2× 2–6
cycles (cycle = 21 days)
Arm B: Paclitaxel 175mg/m2 D1 &
Carboplatin AUC = 5D 2× 2–6
cycles (cycle = 21 days)
NCT01216124 Available Fudan University
(Shanghai,China)
Expanded
Access Neoadjuvant I-IIIA
Docetaxel 75mg/m2 D1 &
Oxaliplatin 130mg/m2 D2 × 6
cycles (cycle = 21 days)8 Chemotherapy Research and Practice
Table 2: Continued.
NCI ID Status Primary location Study type Setting
adjuvant Stage Regimen
NCT01238133 Recruiting
Arthur G. James
Cancer Hospital and
Richard J. Solove
Research Institute at
Ohio State University
Comprehensive Cancer
Center (Columbus,
OH)
Phase I Neoadjuvant II-III
RO4929097 D1-3, 8-10, 15-17 &
Paclitaxel D1, 8, 15 & Carboplatin
D1 × 6 cycles (cycle = 21 days)
NCT01167192 Recruiting
WashingtonUniversity
School of Medicine (St.
Louis, MO)
Phase II Neoadjuvant T2-T4, any N
Cisplatin 75mg/m2 IV or
Carboplatin AUC = 6I V ,a t
physician discretion) + XRT × 6
weeks (50–60Gy to breast/CW;
45–50Gy to internal mammary
nodes, supraclavicular fossa nodes
and axillary nodal basins)
Antiangiogenic agents
NCT00861705 Recruiting Miriam Hospital
(Providence, RI) Phase II Neoadjuvant II-III
Arm A: Paclitaxel D1 weekly × 12
weekly → dd AC D1 × 4c y c l e s
Arm B: Arm A + Bevacizumab
q2wks (weeks 1, 3, 5, 7, 9, 10, 11, 13,
15, 17)
Arm C: Arm A + Carboplatin
q 3 w k s( w k s1 ,4 ,7 ,1 0
Arm D: Arm A + Bevacizumab as in
Arm B + Carboplatin as in Arm C.
NCT01208480 Recruiting Severance Hospital
(Seoul, Korea) Phase II Neoadjuvant II-III
Bevacizumab & Docetaxel &
Carboplatin D1 × 5 cycles (cycle =
21 days → Docetaxel & Carboplatin
C6D1
NCT00777673 Recruiting
University of Tennessee
Cancer Institute
(Memphis, TN)
Phase II Neoadjuvant T2-T3,
cN1-cN2a
Nab-paclitaxel D1, 8, 15 &
Carboplatin D1 & Bevacizumab
D1,15 × 4 cycles (cycle =
28 days) → ddAC × 4 cycles (cycle
= 14 days) & Bevacizumab D1 × 2
cycles (cycle = 14 days)
>4 weeks postoperative:
Bevacizumab D1, 15 × 8c y c l e s
(cycle = 28 days)
NCT00528567 Recruiting Hoﬀmann-La Roche;
International Phase III Adjuvant
Operable
primary
invasive breast
cancer
Arm A: Standard adjuvant
chemotherapy (anthracycline ±
taxane or taxane only) & 1yr of
Bevacizumab 5mg/kg/week dosing
equivalent
Arm B: Standard adjuvant
chemotherapy (anthracycline ±
taxane or taxane only)
NCT00887575 Recruiting Tennessee Oncology,
PLLC (Nashville, TN) Phase I/II Neoadjuvant
T1-3, any N
(excluding
T1N0)
Paclitaxel D1, 8, 15 & Carboplatin
D1 & Sunitinib D1-21 × 6c y c l e s
(cycle = 28 days)
NCT01194869 Recruiting Emory University
(Atlanta, GA) Phase II Neoadjuvant I-IIIA
Sorafenib 400 mg BID throughout
the study: single agent for weeks
1–4, then in combination with
cisplatin followed by dose dense
paclitaxelChemotherapy Research and Practice 9
Table 2: Continued.
NCI ID Status Primary location Study type Setting
adjuvant Stage Regimen
Poly(ADP-ribose) polymerase (PARP) inhibitors
NCT00813956 Recruiting
Stanford
Comprehensive Cancer
Center (Stanford, CA)
Phase II Neoadjuvant I-IIIA Gemcitabine & Carboplatin &
BSI-201 q3wks
NCT01204125 Recruiting
Grupo Espanol de
Estudio Tratamiento y
Otras Estrategias
Experimentales en
Tumores Solidos
(France/Spain)
Phase II Neoadjuvant II-IIIA
Arm A: Iniparib 5.6mg/kg D1, 4
&Paclitaxel 80mg/m2 D1 weekly ×
12 weeks
Arm B: Iniparib 11.2 mg/kg D1
&Paclitaxel 80mg/m2 D1 weekly ×
12 weeks
Arm C: Paclitaxel 80mg/2 D1
weekly × 12 weeks
NCT01074970 Recruiting
Indiana University
Melvin and Bren
SimonCancer Center
(Indianapolis, IN)
Phase II Adjuvant
Residual
disease post
neoadjuvant
chemotherapy
(I-III)
Arm A: PF-01367338 D1-3 C1:
30mg C2-4: 24 mg & Cisplatin
75mg/m2 D1 × 4 cycles (cycle = 21
days)
Arm B: Cisplatin 75mg/m2 D1 × 4
cycles (cycle = 21 days)
EGFR inhibitors
NCT01097642 Recruiting
The Methodist
Hospital Research
Institute (Houston,
TX)
Phase II Neoadjuvant T1N1-3M0 or
T2-4 N0-3M0
Arm A: Cetuximab 400mg/m2 D1
then weekly 250mg/m2 &
Ixabepilone 40mg/m2 D1 1 × 4
cycles (cycle = 21 days)
Arm B: Ixabepilone 40mg/m2 D1
1 × 4 cycles (cycle = 21 days)
NCT00600249 Recruiting
Centre Jean Perrin
(Clermont-Ferrand,
France)
Phase II Neoadjuvant II-IIIa
Cetuximab Wk1D1 400mg/m2 →
250mg/m2 D1 weeks 2–18. &
Docetaxel 100mg/m2 D1 × 6c y c l e s
(cycle = 21 days)
NCT00491816 Active/Not
recruiting
University of Kansas
Medical Center
(Kansas City, KS)
Phase II Neoadjuvant II-III (T2-4,
N1-2)
Erlotinib150 mg orally D3-14 with
cycles 1 to 6 or 3 to 6 of
neoadjuvant chemotherapy.
Adjuvant chemotherapy given at the
discretion of treating physician
followed by 1yr of maintenance
erlotinib 150mg daily
Other targeted agents
NCT00930930 Recruiting
Vanderbilt-Ingram
Cancer Center
(Nashville, TN)
Phase II Neoadjuvant II-III
Arm A: Cisplatin & Everolimus D1
weekly × 12 weeks & Paclitaxel D1
weekly in weeks 4–12
Arm B: Cisplatin & Placebo D1
weekly × 12 weeks & Paclitaxel D1
weekly in weeks 4–12
NCT00499603 Active/Not
recruiting
M.D. Anderson Cancer
Center (Houston, TX) Phase II Neoadjuvant IIa-IIIc
Arm A: Drug: Paclitaxel 80mg/m2
D1 weekly & RAD001 30 mg D1, 8,
15 × 12 cycles (cycle = 21 days) →
5-Fluorouracil 500mg/m2 &
Epirubicin100mg/m2 &
Cyclophosphamide 500mg/m2
D1 × 4 cycles (cycle = 21 days)
Arm B: Paclitaxel 80mg/m2 D1
weekly × 12 cycles (cycle =
21 days) → 5-Fluorouracil
500mg/m2 & Epirubicin100mg/m2
& Cyclophosphamide 500mg/m2
D1 × 4 cycles (cycle = 21 days)
∗Details outlined above as per http://clinicaltrials.gov/; accessed February 28th, 2011.10 Chemotherapy Research and Practice
to assess the pCR rate of erlotinib in combination with
chemotherapy. A second component of this trial involves the
addition of maintenance erlotinib X1 year after the comple-
tion of the patient’s adjuvant regimen. (NCT00491816).
7.Conclusion
Currently, standard chemotherapy remains the cornerstone
of treatment for patients with TNBC in the preoperative
and adjuvant settings. The development of newer biologic
and targeted therapies, such as antiangiogenic agents, EGFR
inhibitors, and PARP inhibitors, continues to be a promising
area of research. Trials are ongoing to assess the eﬃcacy of
speciﬁc chemotherapeutic regimens alone orin combination
with newer targeted agents in both the neoadjuvant and
adjuvant setting and will potentially provide the basis for
practice-altering changes in our management of this high-
risk population. Ideally, clinically appropriate patients with
TNBC should be counseled about the availability of ongoing
clinical trials and whenever possible be treated within the
context of a research study.
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